Pharmaceutical Technology - February 2024

Pharmaceutical Technology - February 2024

Issue link: https://www.e-digitaleditions.com/i/1516147

Contents of this Issue

Navigation

Page 31 of 33

PharmTech.com Bio/Pharma Outsourcing Innovation eBook February 2024 Pharmaceutical Technology ® 31 X X X X X - stock.adobe.com W ith the bio/pharmaceutical indus- try facing patent expirations in the near-term for key drugs, bio/pharma companies are facing the pressure of staying competitive in a bio/pharmaceutical land- scape where the therapies are growing increasing- ly complex amid a major shift toward personalized medicines. Pharmaceutical Technology® spoke with Informa about the critical role outsourcing plays in today's competitive environment as well as into the future. Outsourcing trends PharmTech: What major trends are you seeing in outsourcing in terms of scheduling and availability; advanced therapy medicinal products (ATMPs) being 'rushed' into commercial production; and trends you didn't expect? Informa: Research conducted by the CPHI Cus- tomer Insights team found that key developments for CDMOs/CMOs [contract development and man- ufacturing organizations/contract manufacturing organizations] relate to rising demand for cell and gene therapy (CGT) development and manufactur- ing, as well as biologics, biosimilars, and specialty medications. This demand from bio/pharmaceuti- cal partners may in part be driven by ageing popula- tions around the world and a rise in chronic diseases. The looming expiry of patents [is] also driving bio/ pharmaceutical companies to invest in drug pipe- lines. This demand thus forces bio/pharmaceutical outsourcing vendors to search for ways to remain competitive. The priority for contract organizations is still speed and cost—emphasis is placed on f lexi- ble operations, increased efficiency with continuous manufacturing and digitalization of processes, sup- ply chain resiliency, and end-to-end 'one-stop-shop' ser v ices to cover t he whole va lue chain for t heir Pharmaceutical Outsourcing Present and Chris Spivey is editorial director of Pharmaceutical Technology._ Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.

Articles in this issue

Links on this page

Archives of this issue

view archives of Pharmaceutical Technology - February 2024 - Pharmaceutical Technology - February 2024